FDA Approves Mysterious 'Field Generator Positioning Devices' for Brains
Published Date: 11/26/2025
Rule
Summary
The FDA has officially classified the field generator positioning device as a low-risk, Class I device, making it easier and faster for patients to get access to this helpful technology. This change reduces red tape for manufacturers without compromising safety or effectiveness. The new classification took effect on November 26, 2025, but has been in place since July 10, 2020, so no new costs or delays are expected.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Easier patient access to device
If you are a patient, the FDA has classified the field generator positioning device as Class I (general controls), and says this will enhance patients' access by reducing regulatory burdens. The final order is effective November 26, 2025, and the classification was applicable on July 10, 2020.
Manufacturers face lower premarket burden
If you manufacture or import this device, FDA placed the field generator positioning device in Class I (general controls) and states devices in this type are exempt from premarket notification (510(k)) under section 510(l)(1), except when the device is of substantial importance in preventing impairment of human health or presents a potentially unreasonable risk. FDA says this classification reduces regulatory burdens; the final order is effective November 26, 2025 and was applicable on July 10, 2020.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2025-21217 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Anchored Esophageal Sheath
The FDA is officially classifying the anchored esophageal sheath as a Class II medical device with special safety rules. This change helps make sure the device is safe and effective while making it easier for patients to get access to this helpful technology. The new rules took effect on November 26, 2025, and could reduce some regulatory hurdles for manufacturers.
Next: 2025-21242 — Extending Deadline for Debtor To Request a Waiver
The VA is giving veterans more time—up to one year instead of 180 days—to ask for a waiver on debts related to benefits. This change, effective January 26, 2026, helps reduce stress by giving veterans extra breathing room to handle their debt issues. It doesn’t cost veterans extra money but makes the process friendlier and fairer.